BioSpace News Archive

Predictive Oncology announced today that on August 17, 2021, the stockholders approved an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of Company common stock from 100,000,000 to 200,000,000, and the amendment became effective on August 17, 2021.

BioAgilytix Labs, LLC announced today that it signed a definitive agreement to acquire MicroConstants, adding it to its family of companies.

Ginkgo Bioworks today announced a revenue and business update for the first half of 2021.

KemPharm, Inc. announced today the appointment of Tamara A. Seymour to serve on its Board of Directors and as Chair of the Audit Committee.

AbbVie announced that the New England Journal of Medicine has published 12-week results from the Phase 3 ADVANCE trial evaluating atogepant for the preventive treatment of migraine in adults who meet criteria for episodic migraine.

Senhwa Biosciences, Inc., a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration has granted Fast Track Designation for Silmitasertib, a highly selective inhibitor of casein kinase 2 to treat patients with recurrent sonic hedgehog driven Medulloblastoma.

Pressure BioSciences, Inc. today announced that the Company will host a teleconference to discuss its Second Quarter 2021 financial results and provide a business update.

The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.

MED Institute, a contract research organization dedicated to accelerating client product development, has received designation as an accredited ISO/IEC 17025 laboratory as part of the US Food and Drug Administration Accreditation Scheme for Conformity Assessment.

CardioNXT announced today that it received marketing clearance from the U.S. Food and Drug Administration (FDA) for the platform technology comprised of the iMap 3D Navigation & Mapping System ™ , Activate Software ™ , Sensor Enabled Axis Patient Patches ™ , and MultiLink Sensor Enabled Catheter ™ .